个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC)

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
He, Jie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] * ; Zhang, Xiangru[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Li, Junling[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Han, Baohui[1] ; Liu, Yongyu[2] ; Wu, Shixiu[3] ; Kuang, Y.[4] ; Shen, Yi[5] ; Chen, Chun[6] ; Wang, Qun[7] ; Li, Qiang[8] ; Ma, Haitao[9] ; Xu, Shidong[10] ; Xu, Shaofa[11] ; Wang, P.[12] ; Mao, Weimin[13] ; Pang, Z.[4] ; Hou, S.[14] ; Yang, Y.[15] ;
机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China [2]Liaoning Canc Hosp & Inst, Liaoning, Peoples R China [3]Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China [4]Jiangxi Canc Hosp, Jian, Jiangxi, Peoples R China [5]Qingdao Univ, Coll Med, Affiliated Hosp 1, Qingdao, Peoples R China [6]Fujian Med Univ Union Hosp, Fuzhou, Peoples R China [7]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [8]Sichuan Canc Hosp, Chengtu, Peoples R China [9]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China [10]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [11]Beijing Chest Hosp, Beijing, Peoples R China [12]First Peoples Hosp Yunnan Province, Kunming, Peoples R China [13]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [14]Beijing Chaoyang Hosp, Beijing, Peoples R China [15]Beijing Canc Hosp, Beijing, Peoples R China
出处：
ISSN：

关键词： Endostar Vinorelbine Cisplatin Non-small cell lung cancer (NSCLC)

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2011]版：
大类 | 2 区 医学
小类 | 2 区 呼吸系统 3 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2011]版：
Q1 RESPIRATORY SYSTEM Q2 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者：
第一作者机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China [2]Liaoning Canc Hosp & Inst, Liaoning, Peoples R China [3]Wenzhou Med Coll, Affiliated Hosp 1, Wenzhou, Peoples R China [4]Jiangxi Canc Hosp, Jian, Jiangxi, Peoples R China [5]Qingdao Univ, Coll Med, Affiliated Hosp 1, Qingdao, Peoples R China [6]Fujian Med Univ Union Hosp, Fuzhou, Peoples R China [7]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [8]Sichuan Canc Hosp, Chengtu, Peoples R China [9]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China [10]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [11]Beijing Chest Hosp, Beijing, Peoples R China [12]First Peoples Hosp Yunnan Province, Kunming, Peoples R China [13]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [14]Beijing Chaoyang Hosp, Beijing, Peoples R China [15]Beijing Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
He Jie,Zhang Xiangru,Li Junling,et al.AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC)[J].JOURNAL OF THORACIC ONCOLOGY.2011,6(6):S1318-S1319.
APA：
He, Jie,Zhang, Xiangru,Li, Junling,Han, Baohui,Liu, Yongyu...&Yang, Y..(2011).AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC).JOURNAL OF THORACIC ONCOLOGY,6,(6)
MLA：
He, Jie,et al."AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC)".JOURNAL OF THORACIC ONCOLOGY 6..6(2011):S1318-S1319

相关文献

[1]Endostar plus gemcitabine/cisplatin (GP) with maintenance endostar as first-line therapy for advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study [2]A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result [3]Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC) [4]A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result. [5]TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) [6]Evaluation of Toxicity Profile of ALK Inhibitors in Non-Small Cell Lung Cancer (NSCLC) [7]依托泊苷胶囊在晚期非小细胞肺癌维持治疗临床观察 [8]依托泊苷胶囊在晚期非小细胞肺癌维持治疗临床观察 [9]Acacetin inhibited non-small-cell lung cancer (NSCLC) cell growth via upregulating miR-34a in vitro and in vivo [10]PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study

资源点击量：54684 今日访问量：0 总访问量：4646 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号